Related Experiment Video

Updated: Aug 3, 2026

A Simplified Technique for Producing an Ischemic Wound Model
12:00

A Simplified Technique for Producing an Ischemic Wound Model

Published on: May 2, 2012

17.3K

The Mechanism of Pyroptosis and Its Application Prospect in Diabetic Wound Healing

Abdullah Al Mamun1,2, Chuxiao Shao1, Peiwu Geng1

  • 1Central Laboratory of the Sixth Affiliated Hospital of Wenzhou Medical University, Lishui People's Hospital, Lishui City, Zhejiang, 323000, People's Republic of China.

Journal of Inflammation Research
|March 11, 2024
PubMed

Insights

Pyroptosis, a programmed cell death, is implicated in diabetic complications like diabetic wound healing. Targeting pyroptosis pathways offers potential therapeutic strategies for managing diabetic wounds effectively.

Area of Science:

  • Cell Biology
  • Immunology
  • Pathology

Background:

  • Pyroptosis is a programmed cell death pathway involving gasdermin proteins, leading to inflammation.
  • Canonical and non-canonical pathways mediate pyroptosis, involving caspases.
  • Inflammasomes, particularly NLRP3, activate pyroptosis and inflammation.

Purpose of the Study:

  • To review the molecular mechanisms of pyroptosis.
  • To discuss pyroptosis's role in diabetic wound healing (DWH).
  • To explore therapeutic agents targeting pyroptosis for DWH.

Main Methods:

  • Literature review of pyroptosis mechanisms.
  • Analysis of studies on pyroptosis in diabetic complications.
  • Identification of potential therapeutic compounds targeting pyroptosis.

Main Results:

  • Pyroptosis contributes to the progression of diabetic complications, including DWH and diabetic foot ulcers (DFUs).
  • NLRP3 inflammasome activation is a key driver of pyroptosis and inflammation in these conditions.
  • Targeting pyroptotic pathways shows promise for DWH treatment.

Conclusions:

  • Pyroptosis plays a significant role in the pathogenesis of diabetic wound healing.
  • Therapeutic strategies targeting pyroptosis signaling pathways are emerging for diabetic wound management.
Keywords:
GSDMDNLRP3caspase-1diabetes mellitusdiabetic wound healinginflammasomeinflammationpyroptosis

More Related Videos

Protocol to Create Chronic Wounds in Diabetic Mice06:55

Protocol to Create Chronic Wounds in Diabetic Mice

Published on: September 25, 2019

20.3K
A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

3.8K

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and 'exit' via the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...